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Sunscreens have been advocated as an important means
of preventing skin cancer. Ultraviolet radiation induced
immunosuppression is recognized as an important
event in skin cancer development, yet the e¡ectiveness
of sunscreens in protecting the human immune system
from ultraviolet radiation (i.e. ultraviolet radiation) is
still unclear. The only currently accepted method of
sunscreen rating is the sun protection factor system
based on the prevention of erythema. We determined
immune protection factors for six commercially avail-
able sunscreens using a nickel contact hypersensitivity
model in humans. Both sun protection factor and im-
mune protection factor testing was performed using
the same solar simulated ultraviolet radiation source
and dose^responses were used to determine endpoints
both with and without sunscreens. We found that the
immune protection factor did not correlate with the
sun protection factor; however, immune protection fac-
tor was signi¢cantly correlated to the ultraviolet A pro-
tective capability of the sunscreens, indicating that
sunscreen protection from ultraviolet A is important
for the prevention of ultraviolet immunosuppression,
when there is constant ultraviolet B protection.We re-
commend that sunscreens should be rated against their
immune protective capability to provide a better indi-
cation of their ability to protect against skin cancer. Key
words: sunscreening agents/ultraviolet rays. J Invest Dermatol
121:184^190, 2003
S
kin cancer is a common problem in those of European
descent (Armstrong and Kricker, 1995). The main causa-
tive factor is ultraviolet radiation (UV), although the re-
sponsible wavelengths within this region are unclear.
Animal experimentation has implicated UVB (wave-
lengths 290^320 nm) to be of particular importance, although
UVA (wavelengths 320^400 nm) also plays a part in skin carcino-
genesis (de Gruijl et al, 1993). Indeed UVA has been particularly
implicated in both the opossum (Ley, 1997) and platy¢sh (Setlow
et al, 1993) models of melanoma. Among its many e¡ects on the
skin, UV radiation (UVR) is immunosuppressive: it diminishes
antigen-presenting cell function, induces immunosuppressive cy-
tokine production, and abrogates both contact and delayed-type
hypersensitivity reactions (Streilein et al, 1994; Beissert and
Schwarz, 1999).
UV immunosuppression is an important event in skin carcino-
genesis (Donawho and Kripke, 1991; Kripke, 1994). It is now well
recognized that the chronically immunosuppressed organ trans-
plant population is at increased risk of both melanoma (Jensen
et al, 1999) and nonmelanoma skin cancers especially in sun-ex-
posed sites (Lindelof et al, 2000). Exposure to sunlight and subse-
quent UV immunosuppression also enhances susceptibility to
infectious agents (Jeevan et al, 1992; Norval et al, 1999).
Sunscreens have been used for over 30 y to protect from sun-
burn but despite this the incidence of skin cancer continues to
rise. It is commonly believed that the use of sunscreens will pre-
vent the development of skin cancer and, whereas there is evi-
dence for this in animal models (Bestak and Halliday, 1996a),
there is little evidence for this in humans (WHO, 2001). Two ran-
domized trials have been performed that demonstrate that sunsc-
reens can reduce the incidence of solar keratoses, which are
believed to be skin cancer precursors (Thompson et al, 1993; Nay-
lor et al, 1995). The only randomized control trial that has evalu-
ated the e⁄cacy of sunscreens against epithelial skin cancer
showed that the daily use of sunscreens reduced the incidence of
squamous but not basal cell carcinoma (Green et al, 1999).Trials of
sunscreen protection from melanoma have produced inconclusive
results (Wang et al, 2001) with some studies suggesting that mela-
noma is associated with sunscreen use (Garland et al, 1993). This
could be due to UVA exposure being important in the develop-
ment of melanoma (Ley, 1997) as sunscreens protect from UVB
better than they protect from UVA.
Protection from erythema or sunburn by measurement of the
sun protection factor (SPF) is currently the only internationally
recognized endpoint for the evaluation of sunscreen e¡ectiveness.
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Erythema is primarily caused by UVB (Farr and Di¡ey, 1985)
and, therefore, sunscreens that protect well from UVB but not
UVA e¡ectively prevent sunburn. Studies that have compared
the ability of sunscreens to protect against erythema and immu-
nosuppression have so far yielded con£icting results (reviewed in
Ullrich et al, 1999) (Roberts and Beasley, 1995; Bestak and Halli-
day, 1996a; Moyal et al, 1997; Serre et al, 1997;Walker and Young,
1997; Fourtanier et al, 2000). Most studies only examined one or
two sunscreens. Few studies can be compared with each other as
they have not used the same UV spectral source and method of
sunscreen application to test the various products, both of which
can alter sunscreen performance (Stenberg and Larko, 1985; Ro-
berts et al, 1996). Most importantly, the level of protection from
immunosuppression in humans, which can only be determined
by dose^responses has only been evaluated in a single study of
two sunscreens (Damian et al, 1999a). It is important that the level
of both immune and erythema protection based on UVdose^re-
sponses are measured using identical experimental conditions to
resolve the issue of whether the SPF predicts protection of the
immune system in humans (Young andWalker, 1999) and to eval-
uate the e¡ect of spectral absorbance by the sunscreen on im-
mune protection.
This study therefore compared the immune and sunburn pro-
tection of a range of commercially available sunscreens using the
same UV source and sunscreen application density.We used a pre-
viously described in-vivo human nickel contact hypersensitivity
recall model (Damian et al, 1997) of UV-induced immunosup-
pression to obtain UV dose^responses both with and without
sunscreens and to determine sunscreen immune protection fac-
tors (IPF). In addition, we examined the relationship between
sunscreen UVA protective capability and immune protection.
MATERIALS AND METHODS
Subjects Ninety-nine nickel allergic volunteers aged 18^71y (mean 35.5 y)
were recruited by advertisement from the general population for IPF
studies. None of the volunteers were on immunosuppressive or anti-
in£ammatory medications and they did not have any sun exposure to
their backs for at least 4 wk prior to the study. A separate group of 64
non-nickel allergic volunteers was used for sunscreen SPF testing and 34
for the sunscreen UVA protection factor (UVA-PF) studies. Approval was
obtained from both the Central Sydney Area Health Service and
University of Sydney Ethics Committees in accordance with the Helsinki
Principles. All volunteers gave their informed consent for the studies.
UV source The same UV source was used for both SPF and IPF
determinations. This was an Oriel 1000 W ozone-free xenon arc lamp
(Oriel, Stratford, Connecticut) ¢ltered with two 280^400 nm dichroic
mirrors (Oriel) to reduce the visible and infrared output and an
atmospheric attenuation ¢lter (Oriel, serial number 81017) to approximate
closely solar UV (Fig 1). Irradiance was monitored with a scanning
spectrophotometer (Optronics, Orlando, Florida) and UV output
monitored daily with an IL1350 broadband radiometer using SED 038
(UVA) and SED 240 (UVB) detectors (International Light, Newburyport
MA, USA) calibrated against the source with the spectrophotometer. The
integrated irradiance at the skin surface was 3.4 mWper cm2 UVB, 6.9 mW
per cm2 UVA II, and 19.2 mW per cm2 UVA I.
For the UVA-PF studies, an Oriel 1000 Wxenon arc was used, however,
instead of the atmospheric attenuation ¢lter, a UVC and UVB blocking
¢lter (WG320, Oriel) was used to produce a UVA only spectrum with a
cut-o¡ at 320 nm (Fig 1).
Sunscreens The six commercially available sunscreens were purchased in
Australia in the year 2000 and were all labeled as broad spectrum. Their
ingredients are shown inTable I.
In-vivo SPF determination The Australian guidelines for SPF testing
were followed (Standards Australia, 1998), with 10 volunteers tested per
sunscreen. Sunscreen was applied at a density of 2 mg per cm2 and
allowed to dry for at least 15 min prior to irradiation. Test sites on both
sunscreen-protected and unprotected lower-mid back skin received a
single exposure to a range of doses of UV. The minimal erythema dose
(MED) was determined as the lowest UV dose that resulted in just
perceptible erythema with clearly de¢ned borders 24 h later. The SPF was
calculated as the ratio of the MED of sunscreen-protected skin with that of
unprotected skin in each volunteer.
In-vivo UVA-PF determination The same sunscreen application
method and UV irradiation protocol as for SPF testing was used for the
UVA-PF determinations except that a UVA-only spectrum was used.
Each sunscreen was tested on 10 volunteers. The results were read 2 h after
irradiation and the minimal persistent pigment darkening dose (MPD) was
de¢ned as the lowest UV dose that produced barely perceptible tanning
with clearly de¢ned borders. The UVA-PF was calculated as the ratio of
the MPD of sunscreen-protected to unprotected skin as described by
Chardon et al (1997).
In-vitro sunscreen absorbance determination The spectral absorbance
pro¢les of each sunscreen were obtained, using a Labsphere UV-1000 SPF
analyzer (North Sutton, New Hampshire) with sunscreen applied at 2 mg
per cm2 on to a quartz plate substrate pro¢led with the topography of
human skin derived from casts of human test back skin. Two di¡erent
methods of rating UVA protection were calculated from the absorbance
spectra. The Di¡ey critical wavelength is that wavelength below and
including which 90% of the total UV is absorbed by a sunscreen (Di¡ey,
1994). Higher critical wavelengths therefore indicate better UVA
protection. The Boots UVA ratio is the ratio of the total absorption by a
sunscreen in the UVA region compared with that in the UVB region.
Figure1. Spectral output of UV source.The Oriel 1000 W solar simu-
lator and ¢lters used in this study provided a good approximation to nat-
ural sunlight as de¢ned by COLIPA (1994) in the UV range. The relative
spectral outputs are very similar in the UVB region, whereas approxima-
tion in the UVA region does not di¡er substantially until the longer UVA
wavelengths are reached. This spectra lies within the Australian standard
range (Standards Australia, 1998) for ssUV spectra.The UVA spectrum used
for the UVA-PF studies is also shown.
Table I. Sunscreen ingredients
Sunscreenb
Ingredienta A B C D E F
Titanium dioxide 8.3 4 2 3
Zinc oxide 7.5
Oxybenzone 2.5
Octylmethoxycinnamate 9 8 6 8.5 7.5
4-tert butyl-4-methoxybenzoylmethane 2 2 4.2
4-methylbenzylidene camphor 2.5 5
Octocrylene 10.5
aThe ingredients (%w/w) for each test sunscreen as found on the sunscreen bot-
tles.
bAll sunscreens were purchased commercially and were labeled as broad spec-
trum, containing both UVB and UVA protective ingredients.
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In-vivo IPF determination In-vivo IPF were determined as we have
previously described in detail (Damian and Halliday, 2002). Two 6  6
cm sites were demarcated on each nickel allergic volunteer’s mid-lower
back (Fig 2). One site was randomly allocated to have sunscreen applied
using the same density and method as for SPF and UVA-PF testing. The
contralateral area contained four segments that received four di¡erent
doses of solar-simulated UVR (ssUVR; unprotected UVR), one
unirradiated control that did not receive sunscreen (positive control), and
one unirradiated control treated with sunscreen (positive sunscreen
control). The sunscreen-protected site was divided into six segments each
of which received a di¡erent dose of ssUVR (sunscreen UVR). These UV
doses and sunscreen treatments were repeated daily on 4 consecutive days,
with the same dose being delivered to a particular site each day. All subjects
protected with a particular sunscreen received the same set of UVR doses,
regardless of skin type or individual MED. Sunscreen was applied each day
and washed o¡ with soap and water following irradiation.
Immediately following the ¢nal irradiation, 9 mm Finn chambers
(Epitest, Tuusula, Finland) containing nickel sulfate in a petrolatum base
(Trolab Hermal, Reinbeck, Germany) were applied to each of the sites
and removed after 48 h. Nickel concentrations were individualized by
prior patch testing of each volunteer. Doses that produced con£uent
erythema without vesiculation were used in each volunteer. Twenty-four
hours later, the nickel induced erythema was read using a re£ectance
spectrometer (Diastron, Hampshire, UK). The erythema index (EI) of
each nickel test site was calculated as the di¡erence of the average of four
readings taken at each test site and the average of four readings taken from
adjacent skin.
Data analysis Immunosuppression was calculated at each test site by
subtracting the nickel-induced EI at that test site from the EI of the
unirradiated positive control to determine immunosuppression in
erythema units. The results of 15 volunteers for each sunscreen were
pooled at each UV dose and used to determine UV dose^response curves
with and without sunscreen protection. The level of immunosuppression
for both sunscreen protected and unprotected sites was plotted against
UVdose and linear regression was performed to produce a line of best ¢t.
Paired two-tailed Student’s t tests were used to compare nickel-induced
erythema at each test site with the unirradiated positive control site to
determine whether the immunosuppression reached statistical signi¢cance:
results were considered signi¢cant if po0.05.
Reduction in the nickel-induced EI of irradiated sites equal to 30% of
the mean EI of the unirradiated positive control for that experimental
group was considered to be the lowest level of immunosuppression that
could be reliably and reproducibly detected using this method. The dose
of UV that caused this level of immunosuppression was therefore
considered to be the minimal immunosuppressive dose (MISD), which is
analogous to the MED in SPF testing. This dose of UVR, the MISD, was
calculated from the linear regression analysis of the data. The IPF for each
sunscreen was calculated as the ratio of the MISD of sunscreen protected to
sunscreen-unprotected skin.
Statistical analysis of correlations between SPF, IPF, and other parameters
were performed using a Fisher’s R to Z-test (Statview statistical software,
Abacus Concepts, Berkeley, CA, USA) and results were considered
signi¢cant if po0.05.
RESULTS
Unirradiated nickel control reactions There were no
signi¢cant di¡erences between the unirradiated positive controls
and the unirradiated positive sunscreen controls for any sunscreen
(paired Student’s t test).Thus none of the sunscreens on their own
a¡ected the nickel reaction.
Calculation of MISD and IPF For each sunscreen, IPF were
calculated from the pooled results of 15 volunteers, as shown in
Fig 3 for sunscreen D. Fifteen volunteers were irradiated with
the doses of UV shown on separate segments of sunscreen-
protected or unprotected skin. Each volunteer received the same
UV dose for each of 4 consecutive days. The nickel-induced
contact sensitivity response was quantitated with the re£ectance
spectrometer and immunosuppression was calculated at each UV
dose in each volunteer as the di¡erence between the unirradiated
positive control and the test site. The mean immunosuppression
of the 15 volunteers at each UVdose was plotted against UVdose
and a line of best ¢t calculated by linear regression. To be
consistent between experiments with each sunscreen, 30% of
the positive control for each experiment was used as the cut-o¡
because the immunosuppression at this point was the minimum
level that was statistically signi¢cant in all experiments (po0.05,
paired Student’s t test). For sunscreen D shown in the example,
the mean of the positive control was 73.1 erythema units and
therefore 21.9 (30% of 73.1) erythema units was the cut-o¡. The
Figure 2. Example of UV irradiation doses for IPF testing. Sche-
matic diagram of a volunteer’s lower mid-back showing an example of
UVR irradiation doses given each day for the four irradiation days. All
subjects within an experiment received the same doses of UVR regardless
of skin type. One 6 6 cm area was randomly allocated as the sunscreen-
unprotected side with the contralateral area allocated as the sunscreen-pro-
tected side. Each area was divided into six di¡erent segments. UVR doses
were chosen according to the SPF of each sunscreen. This example gives
the UVR irradiation doses for an SPF 6 sunscreen. The average MED is
243 J per m2. Immediately following the ¢nal irradiation, nickel patches
were applied to each segment. The positive control segment received
neither sunscreen nor UV, the positive sunscreen control received sunscreen
in the absence of UV.
Figure 3. Calculation of MISD and IPF for sunscreen D. UV dose^
response curves both with and without sunscreen protection were deter-
mined by linear regression analysis using data pooled from 15 subjects.
The average of the positive controls was 73.1 erythema units. A cut-o¡ of
30% was chosen as the lowest level of signi¢cant immunosuppression that
could be reliably determined and thus 30% of 73.1¼21.9 EI. The MISD of
both sunscreen protected and sunscreen unprotected sites was thus the UV
dose which caused an immunosuppression of 21.9 EI. These were deter-
mined from the linear regression equation and the IPF then was the ratio
of these MISD.
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UV dose that caused this level of immunosuppression (MISD)
was calculated from the linear regression analysis and the IPF
was the ratio of MISD (sunscreen protected) to MISD
(unprotected). The IPF was calculated in the same way for each
sunscreen and the results are shown inTable II.
Broad-spectrum ranking of sunscreens A summary of the
IPF, SPF, and UVA-PF of all sunscreens is shown in Table II.
SPF and IPF were measured with the same UV source and other
conditions. The SPF supplied by the manufacturer was not used
in these studies. The sunscreens were ranked according to their
UVA-PF. As there is currently no internationally accepted
standard of assessing UVA protection, we used three methods
that have been proposed as standards, namely the Di¡ey critical
wavelength method, the Boots UVA ratio, and the UVA-PF
using persistent pigment darkening. A similar order to the
Di¡ey critical wavelength was obtained with the Boots UVA
ratio, except that the ranking of the two sunscreens with the
least UVA protection, sunscreens A and B, were reversed;
however, using the UVA-PF, the order of the sunscreens did not
correlate as well with either the Di¡ey or Boots methods.
There is no correlation between sunscreen IPF and SPF The
in-vivo SPF for each sunscreen was not predictive of the sunscreen’s
IPF obtained using the nickel contact hypersensitivity model as
there was not a signi¢cant correlation between these protection
factors (Fig 4). Thus immune protection was independent of
erythemal protection. The range of SPF was between 6 and 20,
whereas the range of IPF was between 2 and 21 (Table II). The
sunscreen with the highest SPF (E) did not have the highest IPF
(F), whereas the sunscreen with the lowest SPF (D) did not have
the lowest IPF (A). Both sunscreens A and C have approximately
the same SPF (11 and 10, respectively), whereas sunscreen C has an
IPF approximately four times that of sunscreen A. Sunscreen A
has approximately twice the SPF as sunscreen D (11 vs 6), yet
sunscreen D has three times the IPF of sunscreen A. Conversely,
sunscreens B and C have similar IPF (10 vs 9) but they have
di¡erent SPF (15 vs 10).
Sunscreen IPF but not SPF correlates with sunscreen UVA
protection A signi¢cant positive correlation was observed
between IPF and the Di¡ey critical wavelength (po0.05) (Fig 5).
Similarly, there was also a signi¢cant positive correlation between
IPF and the Boots UVA ratio (po0.05) (Fig 5). Both of these
parameters measure the breadth of a sunscreen’s protection and
thus show that the spectral broadness of a sunscreen is an
important factor for immune protective capability. In addition,
there was a signi¢cant positive correlation between IPF and
UVA-PF (po0.001) this indicates the importance of protection
from UVA in determining sunscreen immune protection
(Fig 6). Conversely, linear regression analysis showed that there
were no signi¢cant correlations between SPF and either the
Di¡ey critical wavelength, Boots UVA ratio, or UVA-PF. These
data indicate that UVA protection is more important for
immune protection than it is for erythemal protection.
DISCUSSION
This is a study to determine the limit of sunscreen protection to
the immune system based on dose^responses in humans for su⁄-
cient numbers of sunscreens to study the issues that are important
for a sunscreen to protect the immune system. A single previous
study (Damian et al, 1999a) determined IPF for two sunscreens,
Table II. In-vivo sunscreen SPF and IPF results compared with Di¡ey critical wavelength, Boots UVA ratio and UVA-PF
UVA protection factorsc
Sunscreen SPFa IPFb Di¡ey critical wavelengthd Boots UVA ratioe UVA-PFf
A 11 2 353 0.36 1.6
B 15 10 368 0.33 2.3
C 10 9 373 0.47 2.8
D 6 7 375 0.52 1.9
E 20 17 378 0.61 4.7
F 16 21 383 0.85 4.5
aSPF and IPF were measured using the same solar simulator system and conditions. SPF was measured following the Australian Standard with the average results of 10
volunteers per sunscreen.
bIPF was determined using groups of 15 volunteers for each sunscreen as shown in the example in Fig 3.
cBoth the Di¡ey critical wavelength and Boots UVA ratio were determined from the in-vitro absorption spectra. The UVA-PF was determined in-vivo by the persistent
pigment darkening method using a UVA-only spectrum for irradiation of the volunteers.
dThe Di¡ey method calculates the wavelength below which 90% of a sunscreen’s absorbance occurs.
eThe Boots UVA ratio is the ratio of a sunscreen’s total UVA absorbance compared with its total UVB absorbance.
fThe UVA-PF indicates the level of UVA protective capability of a sunscreen and was determined by the persistent pigment darkening method.
Figure 4. IPF does not correlate with SPF.The SPF and IPF of the six
test sunscreens were plotted against each other. Each point represents a dif-
ferent sunscreen.There was no signi¢cant correlation between SPF and IPF
(Fisher’s R to Z-test; r2¼ 0.53, p40.05) indicating that the immune protec-
tion of a sunscreen cannot be predicted from its SPF.
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demonstrating that the methodology was appropriate; however,
insu⁄cient numbers of sunscreens were analyzed to dissect the
sunscreen properties that in£uence immune protection. These
properties have important implications for sunscreen product de-
sign and protection from skin cancer.We have demonstrated that
a sunscreen provides better protection against immune suppres-
sion than erythema if it possesses exceptional UVA protection.
This provides a scienti¢c rationale for designing sunscreens that
protect from UVA as they may provide better protection from
skin cancer.
There did not appear to be any association between a particular
sunscreen ingredient and IPF. de Fine Olivarius et al (1999) de-
monstrated that a sunscreen that contained a chemical UV blocker
was more e¡ective at preventing the isomerization of trans-uroca-
nic acid than a sunscreen containing a physical blocker (titanium
dioxide) with the same SPF.Whereas this is an important immu-
nosuppressive mechanism, in our study the worst performing
sunscreen (sunscreen A) and the best performing sunscreen
(sunscreen F) both contained titanium dioxide and chemical
agents. Sunscreen F, however, which was the only sunscreen to
have an IPF greater than its SPF, was the only one to contain oc-
tocrylene. Interestingly, sunscreen F was also the only sunscreen
not to contain octylmethoxycinnamate. Sunscreen A, which per-
formed worst with regard to immune protection was also the
only sunscreen to contain oxybenzone. It has been suggested pre-
viously that the addition of anti-oxidants such as vitamin E may
provide additional UV protection to the immune system (Yuen
and Halliday, 1997) and it is therefore possible that anti-oxidants
in the sunscreens contributed to the IPF. Therefore an examina-
tion of whether immune protection is related to particular sunsc-
reen ingredients would require a more systematic study of this
issue using speci¢cally formulated sunscreens.
We did not ¢nd any correlation between a sunscreen’s ability to
protect against immunosuppression and erythema. This has been
a highly controversial area, which due to a lack of dose^response
data required to establish limits of protection, has not been pre-
viously resolved. Most of the original studies in mice observed
that sunscreens either failed to protect (Reeve et al, 1991) or only
partially protected (Wolf et al, 1993) against UV-induced immu-
nosuppression compared with erythema.The UV sources in these
early studies were often un¢ltered FS-type lamps that contained
contaminating UVC. Using appropriate ssUV sources and meth-
ods based on those used for SPF testing, Roberts and Beasley
(1995) found that commercial sunscreens were able to protect the
immune system at a level exceeding the labeled SPF in mice. It is
important to note that the labeled SPF would have been derived
from human studies (which were not con¢rmed using the same
UV source), yet mice were used to obtain immunosuppression
data. In-vitro dose^response studies performed by Peguet-Navarro
et al (2000) on human skin explants using the mixed epidermal
cell reaction found that the IPF for four sunscreens ranked simi-
larly to their SPF. This study, however, utilized only a UVB
source at 312 nm ignoring the possible e¡ects of UVA on IPF.
Whereas this is the ¢rst study to determine immune protection
limits based on doseresponse curves in a su⁄cient number of
sunscreens to address the factors involved, our ¢ndings are in
agreement with conclusions based on ¢ndings from single UV
dose studies (Bestak et al, 1995; Moyal et al, 1997). These studies
also found that the SPF cannot be considered a satisfactory guide
to sunscreen immune protective capacity. Considering that the
action spectra for erythema and immune suppression are prob-
ably di¡erent, this would not be an unexpected result. UVB is
primarily responsible for erythema (Farr and Di¡ey, 1985),
whereas the action spectrum for immunosuppression in humans
is not known.
The role of the UVA waveband in UV-induced immunosup-
pression is controversial. Some studies ¢nd that UVA is immuno-
suppressive, whereas others ¢nd that it is immunoprotective.
Bestak and Halliday (1996b) demonstrated that UVA radiation
was capable of causing a signi¢cant reduction in the number of
Langerhans cells from the epidermis of mice and of inducing im-
munosuppression. Moyal et al (1997) examined the e¡ects of
UVA on the delayed type hypersensitivity response in humans.
Both UVB together with UVA and UVA alone caused immuno-
suppression both locally and systemically. Using the nickel con-
tact hypersensitivity model in humans used in this study, we have
previously shown that the time course for UVA-induced suppres-
sion di¡ered from the time course for UVB immunosuppression
(Damian et al, 1999b) and that additional UVA can augment
ssUV-induced immunosuppression (Kuchel et al, 2002). Dumay
et al (2001) performed in-vitro studies using epidermal cell suspen-
sions speci¢cally investigating the importance of long-wave-
length UVA in immunosuppression. They found that UVA I
Figure 5. IPF correlates with Di¡ey critical wavelength and Boots
UVA ratio. IPF was plotted against Di¡ey critical wavelength or Boots
UVA ratio. Each point represents a di¡erent sunscreen. There were signi¢-
cant correlations between IPF and both the Di¡ey critical wavelength
(Fisher’s R to Z-test; r2¼ 0.71, po0.05) and the Boots UVA ratio (Fisher’s
R to Z-test; r2¼ 0.72, po0.05), which indicate that the breadth of a sunsc-
reen’s protective capability is important in determining immune protec-
tion.
Figure 6. IPF correlates with UVA-PF.There was a signi¢cant correla-
tion when IPF was compared to the UVA-PF (Fisher’s R to Z-test;
r2¼ 0.93; po0.001) indicating that UVA protection of a sunscreen is an im-
portant determinant of immune protection.
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exposure resulted in both Langerhans cell depletion and downre-
gulation of antigen presenting cell activity.
In contrast, earlier studies into the action spectrum for UV im-
munosuppression by De Fabo and Noonan (1983) and Elmets et al
(1985) did not demonstrate the importance of UVA in immuno-
suppression. These studies, however, used UV sources that were
contaminated with UVC and did not actually investigate wave-
lengths above 320 nm. Studies by Reeve et al (1998) showed that
UVAwas able to protect against UVB-induced immunosuppres-
sion in hairless mice. Skov et al (2000) also demonstrated that
UVA I was able to partially protect against UVB-induced reduc-
tion in immunization rates in humans to epicutaneously applied
antigens. These studies, showing an immunoprotective e¡ect of
UVA, used very high UVA doses. Recently our group has shown
that, whereas low-dose UVA causes immunosuppression, high
doses are immunoprotective, at least in some mouse strains (By-
rne et al, 2002).
The sunscreens used in this study all protected well in the
UVB region but had di¡erent UVA protective abilities as indi-
cated by their di¡erent UVA protection indices. As both UVB
and UVA are immunosuppressive, it is likely that all sunscreens
used in this study provided adequate protection from the UVB
doses used in this study, so that the ability to protect in the
UVA waveband was the limiting factor in preventing immune
suppression from ssUV.
Our ¢ndings that IPF correlates with both the Di¡ey critical
wavelength and Boots UVA ratio clearly demonstrated the im-
portance of the breadth of sunscreen UVB and UVA protection
in order to protect the immune system.This is in agreement with
several previous sunscreen studies that showed that broad-spec-
trum sunscreens protected better than UVB-only sunscreens
against single doses of UV. The ¢rst study to suggest this was in
mice, where a broad-spectrum sunscreen provided greater protec-
tion from a single dose of UV (Bestak et al, 1995). This was later
con¢rmed in humans (Damian et al, 1997) again using a single
dose of UV.
Our results showing the important relationship between im-
mune and UVA protection as determined by UVA-induced per-
sistent pigment darkening extends earlier studies by Fourtanier
et al (2000), who compared two sunscreens with the same SPF
but di¡erent UVA-PF to show that the product with the higher
UVA-PF more e⁄ciently prevented suppression of contact hyper-
sensitivity in mice. These results were con¢rmed in a later study
that showed that the suppression of delayed type hypersensitivity
by full spectrum UVA, UVA I, or ssUV could be prevented by a
sunscreen with a high UVA-PF better than one with lower UVA
protection (Moyal and Fourtanier, 2001). A more recent study
(Nghiem et al, 2001) showed that UVAwas as e¡ective as ssUVR
in suppressing the elicitation of an established immune response
to Candida albicans in mice. A sunscreen containing both UVB
and UVA ¢lters was able to completely prevent this e¡ect,
whereas a UVB-only ¢lter provided no protection.These studies,
however, did not enable the detailed analysis that is only possible
with dose^responses.
There is now a large body of evidence con¢rming the impor-
tance of UV-induced immunosuppression in the development of
skin cancer.We have demonstrated that for a sunscreen to provide
good protection against immunosuppression (i.e., have a high
IPF) it must provide good UVA protection. The importance of
UVA in the etiology of melanoma has been suggested byWang
et al (2001) yet there is controversy as to whether sunscreen use is a
risk factor for the development of melanoma. It is possible that
prolonged sun exposure enabled by the use of sunscreens with
poor UVA protection results in high levels of immunosuppres-
sion, which then contributes to skin cancer development.
In view of the results of this study, we would recommend that
sunscreens should be labeled not only with an SPF, but also an
IPF, to give a more accurate assessment of protection from the
damaging e¡ects of UV. Even though we have shown that the
IPF increases as UVA-PF increases, other factors such as sunscreen
ingredients and other unknown factors may in£uence the pre-
ventive e¡ects from immunosuppression. Hence at this stage it
would be prudent to assess IPF as well as UVA protection for
sunscreens. A standard protocol for IPF determinations would
need to be agreed upon, which had biologic endpoints that were
relevant to human carcinogenesis. This may aid the development
of sunscreens with improved protection from skin cancer.
DrTerence Poon was supported by a University of Sydney Postgraduate Award.This
study was partly funded by a National Health and Medical Research Council Grant.
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